ReviewTherapeutic advances in medical oncology2014
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
Review in Therapeutic advances in medical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana.BMC cancer · 2025Article
- Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.Immunomedicine · 2024Article
- Breast Cancer Heterogeneity.Diagnostics (Basel, Switzerland) · 2021Review
- Tumor Mutation Burden Prediction Model in Egyptian Breast Cancer patients based on Next Generation Sequencing.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3.Journal of experimental & clinical cancer research : CR · 2021Article
- RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.BMC cancer · 2020Article
- Article
- Molecular determinants of drug response in TNBC cell lines.Breast cancer research and treatment · 2020Article
- Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.Oncology letters · 2019Article
- The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors.Iranian journal of pathology · 2019Article
- Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer.Frontiers in genetics · 2019Article
- ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.Oncotarget · 2017Article
- Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Therapeutic advances in medical oncology · 2016Review
- The tandem duplicator phenotype as a distinct genomic configuration in cancer.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.Cancer research · 2016Article
- The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.Breast cancer research : BCR · 2015Article
- Article
- Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2015Article
- Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer.Quantitative imaging in medicine and surgery · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.